145 related articles for article (PubMed ID: 7549062)
1. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.
Morton AJ; Durrant ST
Clin Transplant; 1995 Jun; 9(3 Pt 1):205-8. PubMed ID: 7549062
[TBL] [Abstract][Full Text] [Related]
2. Octreotide in the management of diarrhea induced by graft versus host disease.
Ippoliti C; Neumann J
Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
[TBL] [Abstract][Full Text] [Related]
3. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
Ippoliti C; Champlin R; Bugazia N; Przepiorka D; Neumann J; Giralt S; Khouri I; Gajewski J
J Clin Oncol; 1997 Nov; 15(11):3350-4. PubMed ID: 9363865
[TBL] [Abstract][Full Text] [Related]
4. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topkan E; Karaoglu A
Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
6. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.
Wasserman E; Hidalgo M; Hornedo J; Cortés-Funes H
Bone Marrow Transplant; 1997 Nov; 20(9):711-4. PubMed ID: 9384471
[TBL] [Abstract][Full Text] [Related]
7. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
Liem LM; van Noort JT; Goulmy E
Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
[TBL] [Abstract][Full Text] [Related]
8. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
9. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
[TBL] [Abstract][Full Text] [Related]
10. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
Pai V; Porter K; Ranalli M
Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
[TBL] [Abstract][Full Text] [Related]
11. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
12. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
Mystakidou K; Katsouda E; Tsilika E; Smyrniotis V; Vassiliou I; Tsiatas M; Vlahos L
Anticancer Res; 2006; 26(3B):2325-8. PubMed ID: 16821610
[TBL] [Abstract][Full Text] [Related]
13. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease.
Nishida T; Hamaguchi M; Hirabayashi N; Haneda M; Terakura S; Atsuta Y; Imagama S; Kanie T; Murata M; Taji H; Suzuki R; Morishita Y; Kodera Y
Bone Marrow Transplant; 2004 Jun; 33(11):1143-50. PubMed ID: 15077133
[TBL] [Abstract][Full Text] [Related]
14. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery.
Gullichsen R
Tech Coloproctol; 2006 Dec; 10(4):346-9. PubMed ID: 17115310
[TBL] [Abstract][Full Text] [Related]
15. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
Kanamaru A; Takemoto Y; Kakishita E; Dohy H; Kodera Y; Moriyama Y; Shibata A; Kasai M; Katoh S; Saitoh H
Bone Marrow Transplant; 1995 Jun; 15(6):885-9. PubMed ID: 7581086
[TBL] [Abstract][Full Text] [Related]
16. Progressive autologous graft-versus-host disease induced by cyclosporin A.
Barredo JC; Yusuf U; Hahn A; Abboud MR; Laver J
Bone Marrow Transplant; 1996 Sep; 18(3):659-62. PubMed ID: 8879637
[TBL] [Abstract][Full Text] [Related]
17. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation.
Bianco JA; Higano C; Singer J; Appelbaum FR; McDonald GB
Transplantation; 1990 Jun; 49(6):1194-5. PubMed ID: 2360261
[No Abstract] [Full Text] [Related]
18. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease.
Ely P; Dunitz J; Rogosheske J; Weisdorf D
Am J Med; 1991 Jun; 90(6):707-10. PubMed ID: 2042686
[TBL] [Abstract][Full Text] [Related]
19. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
[TBL] [Abstract][Full Text] [Related]
20. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
